NCT04340024 Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
| NCT ID | NCT04340024 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Centre, Singapore |
| Condition | Nasopharyngeal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2015-09-30 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2015-09-30 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Eligibility Criteria
Inclusion Criteria: * Patients with severe side effects from radiotherapy * Patients with a type of cancer that is associated with sensitivity to radiotherapy Exclusion Criteria: * Age of patient must be between 21 (inclusive) and 99 (exclusive)
Contact & Investigator
Melvin Chua, MD
✉ melvin.chua.l.k@singhealth.com.sgMelvin Chua, MD
PRINCIPAL INVESTIGATOR
National Cancer Centre, Singapore
Frequently Asked Questions
Who can join the NCT04340024 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 99 Years, studying Nasopharyngeal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04340024 currently recruiting?
Yes, NCT04340024 is actively recruiting participants. Contact the research team at melvin.chua.l.k@singhealth.com.sg for enrollment information.
Where is the NCT04340024 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT04340024 clinical trial?
NCT04340024 is sponsored by National Cancer Centre, Singapore. The principal investigator is Melvin Chua, MD at National Cancer Centre, Singapore. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.